Immupharma Share Discussion Threads

[lord loads of lolly] 19/12/2022 19:21

Eva Perone - I fear your destiny is less pharma. More the cappuccino maker.

[halfbutt] 19/12/2022 19:19

Me too eva... hope you still have hammersmith xxx

[eva1989] 19/12/2022 10:14

Booked decent loss

Heartbreaking but I'm now done with IMM.

Onto Destiny Pharma now

[arlington chetwynd talbott] 17/12/2022 13:05

You are maybe confusing me with Arlington Chetwynd Talbot - we are different people.

[andymunchkin] 17/12/2022 12:39

ACT ru the reAlOne orA clone??

[arlington chetwynd talbott] 17/12/2022 12:34

You may be right, but you seem to say that about every share.

[neo26] 16/12/2022 22:42

Well another placing coming?

[ken chung] 16/12/2022 16:15

Timberrrrrrrrr!Lemmings and mushrooms only!

[neo26] 16/12/2022 11:12

What is imm actually doing now?

[supernumerary] 24/11/2022 16:36

Interesting development in lupus treatment:



CAR T cell therapy could reach beyond cancer
by Perelman School of Medicine at the University of Pennsylvania

Engineered immune cells, known as CAR T cells, have shown the world what personalized immunotherapies can do to fight blood cancers. Now, investigators have reported highly promising early results for CAR T therapy in a small set of patients with the autoimmune disease lupus. Penn Medicine CAR T pioneer Carl June, MD, and Daniel Baker, a doctoral student in Cell and Molecular Biology in the Perelman School of Medicine at the University of Pennsylvania, discuss this development in a commentary published today in Cell.

[ ... ]

The commentary from June and Baker comes in response to the first significant clinical report of success from these efforts: a paper in Nature Medicine from German researchers on the use of CAR T therapy against the autoimmune disease lupus (systemic lupus erythematosus).

Researchers say lupus is an obvious choice for CAR T therapy because it too is driven by B cells, and thus experimental CAR T therapies against it can employ existing anti-B-cell designs. B cells are the immune system's antibody-producing cells, and, in lupus, B cells arise that attack the patient's own organs and tissues.

In the German study, the patients—five young adults—did not benefit from standard lupus treatments. Yet, all went into remission, and were able to stop taking their lupus drugs within three months of a single, relatively small dose of CAR T therapy, which essentially removed their existing B cells. (Cancer patients subsequently require infusions of purified human antibodies from healthy volunteers, to maintain some antibody immunity.)

Even more remarkably, all the patients remained in remission during the follow-up period of up to a year, and unlike cancer patients, the lupus patients experienced the return of their B cells, which are naturally replenished from blood stem cells in bone marrow.

[ ... ]

[victor2] 24/11/2022 11:06

Just spotted that stanford have issued an updated research
note this morning can be seen on their website,also on research tree
if you use that.

[neo26] 14/11/2022 18:32

Its true he did say that in interview. Now we know why all those warrants price reduced to 5p, they expected this but mislead investors.

[nobbygnome] 11/11/2022 17:13

Good point neo! It’s shocking really…

[neo26] 11/11/2022 14:15

He mislead us the ceo he said phase 3 was already agreed to last year..

[supernumerary] 11/11/2022 13:12

Nobby - I agree TM has told a lot less than the whole truth. Now find me an AIM CEO of whom that could not be said. Even the saints and sirs, as you know, can bend or avoid the facts to suit their own purposes :¬(

All that said, it will be interesting to see the outcome of the trials, and finally find out for sure whether there is a significant dose-related effect.

[tell sid] 11/11/2022 12:45

OCTP are the place to be, with Phase 1 starting in January and results due in April. Easy 10x bagger.

[nobbygnome] 11/11/2022 11:12

I have been critical of Muller in the past. The science was contradictory and muddled and she completely changed her mind about the site of action. This was a critical part of determining the necessary drug level in vivo to see activity so directly lead to the current issue IMHO.

So SN yes I agree with you to some extent although there is no doubt McCarthy has been economical with the truth all the way through. I still remember him saying in an interview after the phase III results that the trial showed Lupuzor worked. It was a gobsmacking statement because it was the exact opposite of the truth!

[supernumerary] 11/11/2022 11:07

Easy to criticise McCarthy, but if the prize-winning scientist at the centre of all this had done her job as well as he's done his, they wouldn't be in anything like the mess they're currently in. Just saying.

[colsmith] 11/11/2022 10:25

I would say "precise but vague" is what the company are saying; and what does the distribution agreement mean? IMM aren't in to that market are they? Anyhow its clear Avion saw an opportunity to get more than the US rights, whatever it is they wanted. Maybe the good news is that Avion see a future for Lupuzor but at what cost to IMM? Anyhow its impossible to determine precisely what the new test is and speculation is pointless until the cloud clears.

Whoever is pulling the strings at the FDA they certainly got it delayed, unlike Covid stuff - seems some stuff gets tested to detail and other stuff is waved through. Perhaps IMM should have sold rights to GSK or some other deal with a big pharma!

[dunderheed] 11/11/2022 08:02

Oh dear not so good then?
I wouldn't touch anything Tim Mc was involved in after AZM debacle. I thought maybe he had turned a corner....

[nobbygnome] 11/11/2022 07:49

>> waterloo

Yes why would Avion let a company with no sales experience market their drugs. It makes no sense….

[waterloo01] 11/11/2022 07:47

As expected, oh dear. As for the distribution agreement...... really.

[dunderheed] 11/11/2022 07:45

RNS sounds reasonably positive?

[nobbygnome] 11/11/2022 07:41

>> s_k

It’s a tragedy what has happened here because of something so obvious. McCarthy was involved all the way through so should shoulder a lot of the blame